

File No.- BMSIC/40030/771-2025/9315

दिनांक:-28/11/2025

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, बिहार पटना
BMSICL की निविदा संख्या- BMSIC/DRUGS/25-11 से संबंधित प्राप्त ई-निविदाओं के तकनीकी
मूल्यांकन विवरणी पर साक्ष्य सहित दावा/आपत्ति की माँग संबंधी सूचना

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, द्वारा औषधियों की अधिप्राप्ति हेतु ई-निविदा (निविदा संख्या- **BMSIC/DRUGS/25-11**) आमंत्रित की गई थी, जिसके आलोक में निर्धारित समय सीमा के अन्तर्गत कुल 47 (सैंतालीस) ई-निविदा प्राप्त हुई। उक्त 47 (सैंतालीस) ई-निविदा के दस्तावेजों के प्राथमिक तकनीकी मूल्यांकन के उपरान्त तैयार की गई तकनीकी मूल्यांकन विवरणी के दावा/आपत्ति के आमंत्रण हेतु BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** पर अपलोड की गई है।

निविदा में भाग लेने वाले निर्माता संस्थान अथवा अन्य आपूर्तिकर्ता अपलोड किये गए उपर्युक्त तकनीकी मूल्यांकन प्रपत्र में किसी प्रकार की विसंगति पाये जाने की स्थिति में, साक्ष्य सहित अपना दावा/आपत्ति दिनांक 05/12/2025 के अपराह्न 05:00 बजे तक केवल e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के माध्यम से कर सकते हैं।

e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के अलावा अन्य किसी माध्यम से प्राप्त किसी प्रकार के दावा/आपत्ति पर कोई विचार नहीं किया जायेगा।

अनुलग्नक- यथोक्त


महाप्रबंधक (अधिप्राप्ति)

ज्ञापांक:- BMSIC/40030/771-2025/9315

दिनांक:-28/11/2025

प्रतिलिपि :- सहायक प्रबंधक (सिस्टम) एवं प्रबंधक (औषधि) को सूचनार्थ प्रेषित। निदेश है कि सूचना का अनुलग्नक सहित अविलंब BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc2 (**www.eproc2.bihar.gov.in**) पर अपलोड करना सुनिश्चित करें।


महाप्रबंधक (अधिप्राप्ति)



TENDER NO. BMSIC/DRUGS/25-11

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name : - Apple Formulations Pvt. Ltd. Total Number of Pages Submitted in bid documents: - 1 to 151

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein	Yes	38	Yes	
2	3.(b)	b)EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N.No. of drugs quotedEMD Amount 1Upto 5 drugsRs1,00,000/- (One Lakh only) 2For 6 to 10 DrugsRs 2,00,000/- (Two Lakh only) 3For 11 to 15 DrugsRs 3,00,000/- (Three Lakh only) 4For 16 to 20 DrugsRs 4,00,000/- (Four Lakh only) 5More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	Yes	53-56	Yes	
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	13-35	Yes	
4	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted. It's mandatory for the firm to provide a document for the Unique Document Identification Number (UDIN) to verify the documents.	Yes	110-137	Yes	
5	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	Yes	57-59	Yes	
6	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	66	Yes	
7	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	Yes	60-62	Yes	

Anil Kumar Singh

Beena

TENDER NO. BMSIC/DRUGS/25-11

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Apple Formulations Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 151

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	84	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	2-3	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the quoted product.	Yes	94-109	No	Product approval is less than 3 year for NIT sr. no. 7, 9, 17 & 69.
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	94-109	No	
5		•Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years. The Market Standing Certificate must have been issued within preceding one year from the last date of submission of tender (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945. For drugs with a patent that expired less than 2 years ago from the last date of bid submission: Non-patent holding bidders should submit a valid Market Standing Certificate and valid drug license, issued by the State Drug Licensing Authority in support of the claim. Bidders will be eligible only if one batch of new drug has been successfully manufactured/ imported for commercial use at the time of bidding. Bidders should submit document regarding patent expired less than 2 years ago from the last date of bid submission.	Yes	69-79	No	(i) MSC for NIT sr. no. 5, 6, 7, 9, 10, 17, 20, 49 & 63 not issued within preceding one year from the last date of submission of tender. (ii) MSC not submitted for NIT sr. no. 69. (iii) Not submitted for 25 mg for NIT sr. no. 5.
6		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	

Amir
11/11/25Don
12-11-25Anita Balg
11/11/2025Bm
10-11-25

7		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	Yes	89-93	Yes	
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	94-109	No	Product approval is less than 3 year for NIT sr. no. 7, 9, 17 & 69.
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. The Market Standing Certificate must have been issued within preceding one year from the last date of submission of tender. Self-attested copies are to be submitted.	Yes	69-79	No	(i) MSC for NIT sr. no. 5, 6, 7, 9, 10, 17, 20, 49 & 63 not issued within preceding one year from the last date of submission of tender. (ii) MSC not submitted for NIT sr. no. 69. (iii) Not submitted for 25 mg for NIT sr. no. 5.
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	40-52	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandis that the GMP certificate should remain valid till the date of submission of tender.	Yes	10-12	Yes	

Anide
11/11/25

12-11-25

Nitya Balg
11/11/2025

10-11-25

15	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed /Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.	Yes	6-8	Yes	
16	3. (o)	List of items quoted in prescribed format as per Annexure-III duly signed.	Yes	4-5	Yes	
17	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV .	Yes	67-68	Yes	
18	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	85-86	Yes	
19	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	2-3	Yes	
20	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	NA	NA	NA	
21	2(d) Explanation	Explanation- In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in Annexure-VIII	Yes	36-37	Yes	

Anita
11/11/25

Shw

Aditya Bala
11/11/2025

BLN
10-11-25

TENDER NO. BMSIC/DRUGS/25-11

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Apple Formulations Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 151

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Dosage Form		Pack Size		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	5	Atenolol	Atenolol Tablets IP 25 mg	25 mg	Each uncoated Tablet contains: Atenolol IP 25 mg	Tablet	Tablet	10 x 10	Not mentioned	29.01.2015 (page no. 99)	30.12.2027	Generic	(i) Not submitted for 25 mg. MSC not issued within preceding one year from the last date of submission of tender. (page no. 77)
2	6	Atorvastatin	Atorvastatin Tablet IP	10 mg	Each film coated Tablet contains: Atorvastatin Calcium Eq. to Atorvastatin 10 mg	Tablet	Tablet	10 x 10	Not mentioned	13.04.2017 (page no. 100)	30.12.2027	Generic	MSC not issued within preceding one year from the last date of submission of tender. (page no. 78)
3	7	Baclofen	Baclofen Tablet IP	20 mg	Each uncoated Tablet contains: Baclofen IP 20 mg	Tablet	Tablet	10x10	Not mentioned	06.07.2023 (Less than 3 year) (page no. 101)	30.12.2027	Generic	MSC not issued within preceding one year from the last date of submission of tender. (page no. 74)
4	9	B-Complex Syrup	Vitamin B1, Vitamin B2, Nicotinamide, Vitamin B6, Vitamin B12 & Calcium D- pantothenate Syrup for Therapeutic use only Dosage- Two Teaspoonful daily (B-Complex Syrup)	Each 5ml of the medicine contains: thiamine hydrochloride (vitamin B1) 2mg, riboflavin (vitamin B2) 1.2mg, nicotinamide 10mg, pyridoxine hydrochloride (vitamin B6) 1mg and Vitamin B12 2mcg, Calcium D- Pantothenate 10mg	Each 5 ml contains: Vitamin B1 IP 2.0mg Vitamin B2 IP 1.2 mg Nicotinamide IP 10 mg Vitamin B6 IP 1 mg Vitamin B12 IP 2 mcg Calcium D-pantothenate IP 10 mg	Syrup	Syrup	200ml bottle	Not mentioned	06.07.2023 (Less than 3 year) (page no. 102)	30.12.2027	Generic	MSC not issued within preceding one year from the last date of submission of tender. (page no. 74)

Amir
11/11/25

Soms

Rishi Balg
11/11/2025BMS
10-11-25

5	10	Betamethasone Dipropionate	Betamethasone Dipropionate Cream IP	0.05% w/w	Betamethasone Dipropionate IP Eq. to Betamethasone 0.05%	Cream	Cream	15 gm tube	Not mentioned	11.12.2020 (page no. 103)	30.12.2027	Generic	MSC not issued within preceding one year from the last date of submission of tender. (page no. 79)
6	17	Dextromethorphan	Dextromethorphan	8 mg/5 ml	8 mg/5 ml	Oral Syrup	Oral Syrup	60ml Bottle (with measuring Cap)	Not mentioned	06.07.2023 (Less than 3 year) (page no. 101)	30.12.2027	Generic	MSC not issued within preceding one year from the last date of submission of tender. (page no. 74)
7	20	Diethylcarbamazine	Diethylcarbamazine	50mg/5 ml	50mg/5 ml	Oral liquid	Oral liquid	60ml Bottle (with measuring Cap)	Not mentioned	10.10.2014 (page no. 104)	30.12.2027	Generic	MSC not issued within preceding one year from the last date of submission of tender. (page no. 74)
8	36	Glimepiride	Glimepiride	1 mg	1 mg	Tablet	Tablet	10 x 10	Not mentioned	16.04.2016 (page no. 105)	30.12.2027	Generic	Submitted (page no. 70)
9	37	Glimepiride	Glimepiride	2 mg	2 mg	Tablet	Tablet	10 x 10	Not mentioned	16.04.2016 (page no. 105)	30.12.2027	Generic	Submitted (page no. 71)
10	42	Ibuprofen	Ibuprofen	100 mg/5 ml	100 mg/5 ml	Oral liquid	Oral liquid	60ml Bottle	Not mentioned	30.01.2016 (page no. 106)	30.12.2027	Generic	Submitted (page no. 70)
11	49	Levetiracetam	Levetiracetam	100 mg/ml	100 mg/ml	Oral liquid	Oral liquid	100 ml bottle	Not mentioned	18.05.2021 (page no. 107)	30.12.2027	Generic	MSC not issued within preceding one year from the last date of submission of tender. (page no. 73)
12	63	Paracetamol	Paracetamol	500 mg	500 mg	Tablet	Tablet	10 x 10	Not mentioned	07.10.2016 (page no. 108)	30.12.2027	Generic	MSC not issued within preceding one year from the last date of submission of tender. (page no. 75)
13	69	Ramipril	Ramipril	2.5 mg	2.5 mg	Tablet	Tablet	10 x 10	Not mentioned	24.05.2024 (Less than 3 year) (page no. 109)	30.12.2027	Generic	Not submitted

Anita
11/11/23

Ashly Bala
11/11/2023

don

PAN
10.11.24

TENDER NO. BMSIC/DRUGS/25-11

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Apple Formulations Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 151

Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	5	Atenolol	25	139/UA/2007	NA	NA	31.12.2007 (page no. 94)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
2	6	Atorvastatin	25 & 28	139/UA/2007 & 153/UA/SC/P-2007	NA	NA	31.12.2007 (page no. 94-95)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
3	7	Baclofen	25	139/UA/2007	NA	NA	31.12.2007 (page no. 94)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
4	9	B-Complex Syrup	28	153/UA/SC/P-2007	NA	NA	31.12.2007 (page no. 95)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
5	10	Betamethasone Dipropionate	28	153/UA/SC/P-2007	NA	NA	31.12.2007 (page no. 95)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
6	17	Dextromethorphan	25	139/UA/2007	NA	NA	31.12.2007 (page no. 94)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)

Anita
11/11/25Nitya Balg
11/11/2025

Dm

DM
10/11/25

7	20	Diethylcarbamazine	25	139/UA/2007	NA	NA	31.12.2007 (page no. 94)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
8	36	Glimepiride	25	139/UA/2007	NA	NA	31.12.2007 (page no. 94)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
9	37	Glimepiride	25	139/UA/2007	NA	NA	31.12.2007 (page no. 94)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
10	42	Ibuprofen	25 & 28	139/UA/2007 & 153/UA/SC/P-2007	NA	NA	31.12.2007 (page no. 94-95)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
11	49	Levetiracetam	25	139/UA/2007	NA	NA	31.12.2007 (page no. 94)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
12	63	Paracetamol	25	139/UA/2007	NA	NA	31.12.2007 (page no. 94)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)
13	69	Ramipril	25	139/UA/2007	NA	NA	31.12.2007 (page no. 94)	30.12.2027 (page no. 98)	01.10.2022	29.03.2026 (page no. 12)

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/771-2025/8591 dt 07.11.2025 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due deligence and care.Inspite, some inadvertent discreprencies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discreprencies are observed for rectification.

Amrta
11/11/25

Neelam Bala
11/11/2025

Sanu

BM
10-11-25